| Overview |
| bs-13595R-Cy5.5 |
| Dppa4 Polyclonal Antibody, Cy5.5 Conjugated |
| IF(IHC-P), IF(IHC-F), IF(ICC) |
| Human, Mouse, Rat |
| Specifications |
| Cy5.5 |
| Rabbit |
| KLH conjugated synthetic peptide derived from human Dppa4 |
| 51-150/304 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| Nucleus |
| 2410091M23Rik; Developmental pluripotency associated 4; Developmental pluripotency associated protein 4; Developmental pluripotency-associated protein 4; Dppa 4; DPPA4; DPPA4_HUMAN; FLJ10713. |
| DPPA4 (developmental pluripotency associated 4) is a 304 amino acid protein that localizes to the nucleus and is thought to be involved in the maintenance of cell pluripotentiality during embryogenesis. The gene encoding DPPA4 maps to human chromosome 3, which houses over 1,100 genes, including a chemokine receptor (CKR) gene cluster and a variety of human cancer-related gene loci. Key tumor suppressing genes on chromosome 3 include those that encode the apoptosis mediator RASSF1, the cell migration regulator HYAL1 and the angiogenesis suppressor SEMA3B. Marfan Syndrome, porphyria, von Hippel-Lindau syndrome, osteogenesis imperfecta and Charcot-Marie-Tooth Disease are a few of the numerous genetic diseases associated with chromosome 3. |
| Application Dilution |
| IF(IHC-P) |
1:50-200 |
| IF(IHC-F) |
1:50-200 |
| IF(ICC) |
1:50-200 |
Powered by Bioz